Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer

Status:	Completed
Conditions:	Cancer, Cancer, Pancreatic Cancer
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	18 - Any
Updated:	4/21/2016
Start Date:	June 2011
End Date:	March 2015

Placebo-controlled Double-blind Trial of Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer

The purpose of this study is to determine whether patients with locally advanced pancreatic
cancer who receive dasatinib added to standard of care (gemcitabine) live longer, compared
to patients who receive standard of care (gemcitabine) plus placebo; i.e. gemcitabine alone.

Inclusion Criteria:

- Histologic or cytologic documentation of unresectable adenocarcinoma of the pancreas.

- Recovery from toxicity of previous procedures to establish the diagnosis. ECOG PS 0
or 1.

- Adequate organ function.

Exclusion Criteria:

- Evidence of metastatic disease.

- Previous radiotherapy or chemoradiotherapy.

- History of or current pleural effusion.

- History of significant cardiovascular disease.

- Clinically significant bleeding disorder or coagulopathy.

- Concomitant medication with strong CYP 3A4 inhibitor.

We found this trial at

sites

Clinical Trial Facility in Blacktown New South Wales

216 Blacktown Road
Blacktown, New South Wales 2756

from

Blacktown,